Human Subjects: PBPK Modeling of Fenebrutinib
The study utilized a pharmacokinetic modeling approach to predict the cerebrospinal fluid (CSF) concentrations of fenebrutinib in MS patients. The predictions showed good alignment with observed data, indicating effective brain penetration of this drug.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These findings suggest that fenebrutinib may reach the brain effectively, which is crucial for its potential therapeutic effects in treating MS. However, the study does not provide direct clinical trial results or evidence of treatment efficacy.
What this does not prove
The research focuses solely on modeling data and lacks explicit clinical trial outcomes for fenebrutinib.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Laboratory
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-05
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceUtilization of Brain Physiologically Based Pharmacokinetic Modeling in Support of CNS Drug Development: Case Example of Fenebrutinib. ↗DOI: 10.1208/s12248-026-01277-0
Supporting passages (8)
study phaseThis work demonstrates the utility of PBPK modeling to enable prospective CNS exposure prediction and support early clinical decision-making.
study designIn this study, a bottom-up PBPK approach was utilized prospectively to predict human cerebrospinal fluid (CSF) concentrations of fenebrutinib.
subjectsgood brain penetration in multiple sclerosis (MS) patients, which were available afterward.
speciesgood brain penetration in multiple sclerosis (MS) patients, which were available afterward.
peer reviewedJournal: The AAPS journal
findingsThese predictions aligned well with observed CSF data as predicted values fell within 1.5 fold of the observed measurements, indicating the fenebrutinib has good brain penetration in multiple sclerosis (MS) patients, which were available afterward.
publication datePublication date: 2026-10-05
limitationsTitle: Utilization of Brain Physiologically Based Pharmacokinetic Modeling in Support of CNS Drug Development: Case Example of Fenebrutinib.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.